This Pancreatic Cancer Treatment Currently In Development Just Got Orphan Drug Designation
source: pixabay.com

This Pancreatic Cancer Treatment Currently In Development Just Got Orphan Drug Designation

According to an article from kait8.com, the pharmaceutical company Yisheng Biopharma announced that YS-ON-001, a leading candidate for the company, received Orphan Drug Designation from the U.S. Food and Drug…

Continue Reading This Pancreatic Cancer Treatment Currently In Development Just Got Orphan Drug Designation
A Widely Popular Allergy Medication Could Prevent Relapse in Neuromyelitis Optica
source: pixabay.com

A Widely Popular Allergy Medication Could Prevent Relapse in Neuromyelitis Optica

According to an article from brightsurf.com, a commonly used allergy medication called cetirizine (commonly marketed under the name Zyrtec) was able to prevent relapse in patients with neuromyelitis optica in…

Continue Reading A Widely Popular Allergy Medication Could Prevent Relapse in Neuromyelitis Optica
The City of Hope Just Received Millions in Funding To Test A New Procedure to Treat Sickle Cell Disease
source: pixabay.com

The City of Hope Just Received Millions in Funding To Test A New Procedure to Treat Sickle Cell Disease

According to a story from bioportfolio.com, The California Institute for Regenerative Medicine has given $5.74 million to the City of Hope, a private, nonprofit clinical research center that is primarily…

Continue Reading The City of Hope Just Received Millions in Funding To Test A New Procedure to Treat Sickle Cell Disease
Virtual Reality Platform Utilized At Boston Children’s Hospital and Klick Health
Source: Pixabay

Virtual Reality Platform Utilized At Boston Children’s Hospital and Klick Health

A new medical educational platform called the HealthVoyager has been released and is now being utilized following a collaboration with the Boston Children's Hospital and Klick Health, reports PR News…

Continue Reading Virtual Reality Platform Utilized At Boston Children’s Hospital and Klick Health
An Experimental Drug for Batten Disease Just Got Orphan Drug Designation From The EMA
Source: Pixabay

An Experimental Drug for Batten Disease Just Got Orphan Drug Designation From The EMA

According to an article from kait8.com, the pharmaceutical company Polaryx announced that its experimental drug PLX-200 has received Orphan Drug Designation from the European Medicines Agency (EMA) for the treatment…

Continue Reading An Experimental Drug for Batten Disease Just Got Orphan Drug Designation From The EMA